M 1001
Alternative Names: M-1001; MEDICA M1001Latest Information Update: 18 Feb 2022
At a glance
- Originator SyndromeX
- Class Antihyperlipidaemics
- Mechanism of Action AMP activated protein kinase modulators; FOXO1 protein expression modulators; Hepatocyte nuclear factor 4 modulators; Mitochondrial permeability transition pore modulators; STAT3 transcription factor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Dyslipidaemias
Most Recent Events
- 18 Feb 2022 Discontinued - Phase-II for Dyslipidaemias in Israel (PO)
- 18 Feb 2022 No development reported - Phase-II for Dyslipidaemias in Israel (PO), prior to February 2022
- 25 Jul 2016 Phase-II clinical trials in Dyslipidaemias in Israel (PO)